Oliver Wyman, a global management consulting firm and a business of Marsh McLennan [NYSE: MMC] today announced that it has entered into an agreement to acquire Huron’s life sciences strategy consulting practice.
Huron is recognized in the market for its expert life sciences strategy business, helping clients address their most important commercial, marketing, pricing, market access, and R&D challenges. Huron’s senior professionals have longstanding relationships as trusted advisors with many of the world’s top pharmaceutical, biotechnology, diagnostics, and medical device companies.
Once the transaction closes, the Huron team will deliver even greater impact for their clients through the insights of Oliver Wyman partners who serve health insurers, pharmacy benefit managers, and healthcare providers, as well as the Oliver Wyman Health Innovation Center community. In addition, life sciences companies will now have greater access to Oliver Wyman’s actuarial, organizational effectiveness, digital, and operations capabilities.
“The entire healthcare industry, including life sciences, is under tremendous pressure,” said Nick Studer, President and CEO, Oliver Wyman. “The past year has shown the transformative impact life sciences companies can have, and Oliver Wyman is committed to working with them to make lifesaving innovation affordable and accessible to all. Having this experienced team join us from Huron will allow Oliver Wyman to have an even greater impact on the healthcare industry.”
“Combining Oliver Wyman’s global focus and capabilities with Huron’s deep industry expertise will provide the scale needed to support the increasingly complex commercialization and access-related issues facing life sciences organizations,” said James H. Roth, chief executive officer of Huron.
Approximately 80 professionals, including 12 partners, will join Oliver Wyman’s Health and Life Sciences practice led by Oliver Wyman partner Sam Glick. John Westwood, who currently leads Huron’s life sciences strategy consulting business, will lead Oliver Wyman’s global life sciences team when the deal closes.
The terms of the transaction were not disclosed. The deal is expected to close before the end of the year.
To read the original article
CLICK HERE.
